Biotech

All Articles

Actinogen's cortisol blocker stops working period 2 anxiety research

.Actinogen Medical's cortisol blocker has actually missed the main endpoint of a period 2 research s...

Bivictrix determines going personal only method to take ADC in to center

.Antibody-drug conjugates (ADCs) have actually been at the facility of several a billion-dollar biob...

TPG leadings up funds to $580M for assets all over lifestyle scientific researches

.Property manager TPG, which has actually sustained biotechs including Sionna Therapeutics and Santa...

Merck ceases period 3 TIGIT trial in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT program has endured another drawback. Months after shuttering a period 3 can...

After a tough year, Exscientia folds into Recursion

.After a year described through pipeline cuts, the departure of its chief executive officer as well ...

Cullinan, after $25M deal, return bispecific to Harbour

.Cullinan Therapy was excited enough along with Port BioMed's bispecific immune system reactor that ...

A more detailed consider Tough Biotech's Fierce 15

.In this particular week's episode of "The Best Line," our experts are actually diving into Intense ...

Lilly faces stage 2 failure of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's event commemorating the commendation...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of substantial management hirings, firings a...

Lykos are going to talk to FDA to rethink its decision observing turndown of MDMA therapy for post-traumatic stress disorder

.Complying with a poor showing for Lykos Therapies' MDMA prospect for post-traumatic stress disorder...